Scribe Review: Shades of The Conversation and The Lives of Others colour this French thriller from Thomas Kruithof, about a man (François Cluzet) who is offered a job transcribing surveillance recordings. The ominous chill of the sound design and decent work from an impressive cast help to create an atmosphere that sucks the very oxygen from the cinema as the tension mounts. Unfortunately, too many layers of convoluted double-crossing, and motives as murky as the grim production design, rob the film of a satisfying sign-off.
Alternative to: MySignature
Track and analyze signature conversion rates, as well as schedule changes for marketing campaigns or banners
Setup is practically plug-and-play as well. After screwing in an antenna, plugging in the power adapter, and connecting the box to your router with an ethernet cable, you can visit the my.hdhomerun website to finish the setup. SiliconDust sells two versions of the Scribe: The $200 Duo can play and/or record up to two channels at a time, and the $250 Quatro can play and/or record up to four channels simulltaneously.
Scribe fits all its wheels with what it calls ‘endurance bearings’ (there’s a ‘race bearings’ upgrade available at the point of ordering) – sealed stainless steel units designed as much for longevity and all-year use as for performance.
See related Buyer’s guide: Best disc wheelsets Best smart turbo trainers: Top Zwift compatible indoor trainers Rapha Festive 500: Christmas cycling challenge confirmed for an 11th year on Strava Best road bikes: the best bikes on the market from £729 to over £10, 000 Scribe Aero Wide+ 32 carbon disc wheelset review
Scribe Therapeutics and Biogen $415 Million Deal Is Under
Scribe Therapeutics has only been around since 2018, but the company is already making noise in the market. Experts in the CRISPR-based genetic medicine started the Berkeley, Calif. company. On Oct. 6, the company unveiled the fully integrated platform alongside a Biogen deal reportedly worth more than $415 million.
The Scribe Therapeutics and Biogen deal
At the same time, Scribe unveiled their genetic platform and announced the forthcoming deal with Biogen, Inc. Biogen’s initial $15 million investment—plus $400 million in milestone investments—is going toward research in neurodegenerative diseases like amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.